Clinical Trial

A Study of GlcNAc on Tear Production in NGLY1-CDDG

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In patients with NGLY1-CDDG, the disorder can lead to eye damage due to not being able to produce enough tears. This study is being done to see if the dietary supplement, GlcNAc, improves tear production in patients with NGLY1-CDDG.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2022-05-28; most recent amendment 2025-07-03.
Status change: Recruiting → Active, Not Recruiting 2025-07-03
Status change: Not Yet Recruiting → Recruiting 2025-01-16
Trial Details
NCT Number NCT05402345
Lead Sponsor Eva Morava-Kozicz
Collaborators: Children's Hospital of Philadelphia, Seattle Children's Hospital
Conditions NGLY1 Deficiency
Enrollment 18 participants
Start Date 2025-01-24
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-08